Soliris® (eculizumab) (Intravenous)

Length of Authorization
- **PNH and aHUS**: Coverage will be provided for twelve (12) months and may be renewed.
- **gMG and NMOSD**: Initial coverage will be provided for six (6) months and may be renewed annually thereafter.

Dosing Limits

**A. Quantity Limit (max daily dose) [NDC Unit]:**

**Loading Doses:**
- 3 vials Days 1, 8, 15, & 22; then 4 vials Day 29

**Maintenance Dose:**
- 4 vials every 14 days

**B. Max Units (per dose and over time) [HCPCS Unit]:**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Loading Doses</th>
<th>Maintenance Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>PNH</td>
<td>60 billable units Days 1, 8, 15, &amp; 22; then 90 billable units Day 29</td>
<td>90 billable units every 14 days</td>
</tr>
<tr>
<td>aHUS, gMG, NMOSD</td>
<td>90 billable units Days 1, 8, 15, &amp; 22; then 120 billable units Day 29</td>
<td>120 billable units every 14 days</td>
</tr>
</tbody>
</table>

Initial Approval Criteria

Site of care specialty infusion program requirements are met (refer to Moda Site of Care Policy).

Coverage is provided in the following conditions:
- **Patient is at least 18 years of age (unless otherwise specified): AND**
• Prescriber is enrolled in the Soliris Risk Evaluation and Mitigation Strategy (REMS) program: AND

Universal Criteria

• Patient must be vaccinated against meningococcal disease at least two weeks prior to initiation of therapy and will continue to be revaccinated according to current medical guidelines for vaccine use (If urgent Soliris therapy is indicated in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide patients with two weeks of antibacterial drug prophylaxis): AND

• Patient does not have an unresolved, serious systemic infection (e.g., Neisseria meningitidis, etc.): AND

• Will not be used in combination with another complement-inhibitor therapy (i.e., ravulizumab, pegcetacoplan) [Note: a 4-week run-in period is allowed when transitioning from eculizumab to pegcetacoplan]: AND

Paroxysmal Nocturnal Hemoglobinuria (PNH) † Φ 1,2,6,9,16

• Diagnosis must be accompanied by detection of PNH clones of at least 10% by flow cytometry diagnostic testing: AND
  o Demonstrate the presence of at least 2 different glycosylphosphatidylinositol (GPI) protein deficiencies (e.g., CD55, CD59, etc.) within at least 2 different cell lines (e.g., granulocytes, monocytes, erythrocytes): AND

• Patient has laboratory evidence of significant intravascular hemolysis (i.e., LDH ≥1.5 x ULN) and at least one other indication for therapy from the following:
  o Presence of a thrombotic event
  o Presence of organ damage secondary to chronic hemolysis (i.e., renal insufficiency, pulmonary insufficiency or hypertension)
  o Patient is pregnant and potential benefit outweighs potential fetal risk
  o Patient has symptomatic anemia (regardless of transfusion dependence)
  o Patient has disabling fatigue
  o Patient has abdominal pain requiring admission or opioid analgesia: AND

• Documented baseline values for one or more of the following (necessary for renewal): serum lactate dehydrogenase (LDH), hemoglobin level, packed RBC transfusion requirement, and history of thrombotic events

  • Patient had an inadequate response, or has a contraindication or intolerance, to ravulizumab-cwvz [Ultomiris™]

Atypical Hemolytic Uremic Syndrome (aHUS) † Φ 1,7,8,10,17

• Patient is at least 2 months of age: AND
• Patient shows signs of thrombotic microangiopathy (TMA) (e.g., changes in mental status, seizures, angina, dyspnea, thrombosis, increasing blood pressure, decreased platelet count, increased serum creatinine, increased LDH, etc.): AND

• Thrombotic Thrombocytopenic Purpura (TTP) has been ruled out by evaluating ADAMTS-13 level (i.e., ADAMTS-13 activity level ≥ 10%): AND

• Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS) has been ruled out: AND

• Other causes have been ruled out such as coexisting diseases or conditions (e.g., bone marrow transplantation, solid organ transplantation, malignancy, autoimmune disorder, drug-induced, malignant hypertension, HIV infection, etc.), Streptococcus pneumoniae or Influenza A (H1N1) infection, or cobalamin deficiency: AND

• Documented baseline values for one or more of the following (necessary for renewal): serum lactate dehydrogenase (LDH), serum creatinine/eGFR, platelet count, and plasma exchange/infusion requirement

• Patient had an inadequate response, or has a contraindication or intolerance, to ravulizumab-cwvz [Ultomiris™]

Generalized Myasthenia Gravis (gMG) † Φ 1,11,12

• Patient has Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to IV disease: AND

• Patient has a positive serologic test for anti-acetylcholine receptor (AchR) antibodies: AND

• Physician has assessed the baseline Quantitative Myasthenia Gravis (QMG) score: AND

• Patient has a MG-Activities of Daily Living (MG-ADL) total score of ≥6: AND

• Patient had an inadequate response after a minimum one year trial with either:
  o Two (2) or more immunosuppressive therapies (e.g., azathioprine, cyclosporine, mycophenolate, etc.): OR
  o One (1) immunosuppressive therapy AND required chronic plasmapheresis or plasma exchange (PE) or intravenous immunoglobulin (IVIG)

• Patient had an inadequate response, or has a contraindication or intolerance, to rituximab

Neuromyelitis Optica Spectrum Disorder (NMOSD) † Φ 1,13-15

• Patient has a confirmed diagnosis based on the following:
  o Patient was found to be seropositive for aquaporin-4 (AQP4) IgG antibodies: AND
  o Patient has at least one core clinical characteristic §: AND
  o Alternative diagnoses have been excluded (e.g., multiple sclerosis, sarcoidosis, cancer, chronic infection, etc.): AND

• Patient has a history of at least 2 relapses in the last 12 months OR 3 relapses in the last 24 months, with at least 1 relapse in the last 12 months: AND
• Patient has an Expanded Disability Status Score (EDSS) of ≤ 7.0 (i.e., presence of at least limited ambulation with aid): **AND**

• Patient is receiving concurrent corticosteroid therapy of 20 mg per day or less and those receiving immunosuppressive therapy (e.g., azathioprine, glucocorticoids, mycophenolate, etc.) are on a stable dose regimen: **AND**

• Patient has not received therapy with rituximab or mitoxantrone in the last 3 months: **AND**

• Patient has not received intravenous immune globulin (IVIG) in the last 3 weeks: **AND**

• Patient had an inadequate response, or has a contraindication or intolerance, to rituximab OR inebilizumab: **AND**

• Patient will not concomitantly receive therapy with any of the following:
  - IL6-inhibitor (e.g., satralizumab): **AND**
  - Anti-CD20-directed antibody (e.g., rituximab): **AND**
  - Anti-CD19-directed antibody (e.g., inebilizumab)

### § Core Clinical Characteristics of NMOSD

- Optic neuritis
- Acute myelitis
- Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting
- Acute brainstem syndrome
- Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
- Symptomatic cerebral syndrome with NMOSD-typical brain lesions

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); ‡‡ Orphan Drug

### IV. Renewal Criteria

Coverage may be renewed based upon the following criteria:

• Patient continues to meet the universal and other indication-specific relevant criteria identified in section III: **AND**

• Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: serious meningococcal infections (septicemia and/or meningitis), infusion reactions, serious infections, thrombotic microangiopathy complications (TMA), etc.: **AND**

• Disease response indicated by one or more of the following:
  - **PNH**
    - Decrease in serum LDH from pretreatment baseline
    - Stabilization/improvement in hemoglobin level from pretreatment baseline
    - Decrease in packed RBC transfusion requirement from pretreatment baseline
    - Reduction in thromboembolic events
  - **aHUS**
- Decrease in serum LDH from pretreatment baseline
- Stabilization/improvement in serum creatinine/eGFR from pretreatment baseline
- Increase in platelet count from pretreatment baseline
- Decrease in plasma exchange/infusion requirement from pretreatment baseline
  - **gMG**
    - Improvement of at least 3-points from baseline in the Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL) total score
    - Improvement of at least 5-points from baseline in the Quantitative Myasthenia Gravis (QMG) total score
  - **NMOSD**
    - Stabilization/improvement of neurologic symptoms as evidenced by a decrease in acute relapses, EDSS, hospitalizations, or plasma exchange treatments

### V. Dosage/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose*</th>
</tr>
</thead>
</table>
| **Paroxysmal nocturnal hemoglobinuria (PNH)** | **Loading dose:**  
- 600 mg intravenously every 7 days for the first 4 weeks, followed by 900 mg intravenously for the fifth dose 7 days later  
**Maintenance dose:**  
- 900 mg intravenously every 14 days |
| **Atypical hemolytic uremic syndrome (aHUS)** | **Adults**  
**Loading dose:**  
- 900 mg intravenously every 7 days for the first 4 weeks, followed by 1,200 mg intravenously for the fifth dose 7 days later  
**Maintenance dose:**  
- 1200 mg intravenously every 14 days  
**Patients < 18 years**  
5 kg - <10 kg:  
- 300 mg weekly x 1 dose, 300 mg at week 2, then 300 mg every 3 weeks  
10 kg - <20 kg:  
- 600 mg weekly x 1 dose, 300 mg at week 2, then 300 mg every 2 weeks  
20 kg - <30 kg:  
- 600 mg weekly x 2 doses, 600 mg at week 3, then 600 mg every 2 weeks  
30 kg - <40 kg:  
- 600 mg weekly x 2 doses, 900 mg at week 3, then 900 mg every 2 weeks  
> 40 kg:  
- 900 mg weekly x 4 doses, 1200 mg at week 5, then 1200 mg every 2 weeks |
| **Generalized Myasthenia Gravis (gMG)** | **Loading dose:**  
- 900 mg intravenously every 7 days for the first 4 weeks, followed by 1,200 mg intravenously for the fifth dose 7 days later |

---

Moda Health Plan, Inc. Medical Necessity Criteria

Proprietary & Confidential

© 2021 Magellan Health, Inc.
and Neuromyelitis Optica Spectrum Disorder (NMOSD)

<table>
<thead>
<tr>
<th>Maintenance dose:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1200 mg intravenously every 14 days</td>
</tr>
</tbody>
</table>

### Dose Adjustment for aHUS (adult and pediatric patients), gMG (adult patients), and NMOSD (adult patients) in case of Plasmapheresis, Plasma Exchange or Fresh Frozen Plasma Infusion

<table>
<thead>
<tr>
<th>Type of Plasma Intervention</th>
<th>Most Recent Soliris Dose</th>
<th>Supplemental Soliris With Each Plasma Intervention</th>
<th>Timing of Supplemental Soliris Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasmapheresis or plasma exchange (PE)</td>
<td>300 mg</td>
<td>300 mg per each plasmapheresis or PE</td>
<td>Within 60 minutes after each plasmapheresis or PE</td>
</tr>
<tr>
<td>≥ 600 mg</td>
<td>600 mg per each plasmapheresis or PE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fresh frozen plasma infusion (FFP)</td>
<td>≥ 300 mg</td>
<td>300 mg per each infusion of FFP</td>
<td>60 minutes prior to each infusion of FFP</td>
</tr>
</tbody>
</table>

*Doses should be administered at the above intervals, or within two days of these time points.*

### VI. Billing Code/Availability Information

**HCPCS Code:**

J1300 – Injection, eculizumab, 10 mg; 1 billable unit = 10 mg

**NDC:**

Soliris 300 mg/30 mL single-use vials for injection: 25682-0001-xx

### VII. References


3. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcić MF; Rother RP. N Engl J Med 2004 Feb 5;350(6):552-9.

4. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. Hillmen P; Young NS; Schubert J; Brodsky RA; Socie G; Muus P; Roth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcić CF; Rother RP; Luzzatto L. N Engl J Med. 2006 Sep 21;355(12):1233-43.
5. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of
patients with paroxysmal nocturnal hemoglobinuria. Brodsky RA; Young NS; Antonioli E;
Risitano AM; Schrezenmeier H; Schubert J; Gaya A; Coyle L; de Castro C; Fu CL;
Maciejewski JP; Bessler M; Kroon HA; Rother RP; Hillmen P. Blood. 2008 Feb
Jan;148(1):37-47.
1528.
acetylcholine receptor antibody-positive refractory generalised myasthenia gravis
(REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).
J Neurol 2014; 261:1.
Jun 19.
consensus statement of the Canadian PNH Network and review of the national registry. Eur
(A54548). Centers for Medicare & Medicaid Services, Inc. Updated 06/25/2021 with effective
Appendix 1 – Covered Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D59.3</td>
<td>Hemolytic-uremic syndrome</td>
</tr>
<tr>
<td>D59.5</td>
<td>Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]</td>
</tr>
<tr>
<td>G36.0</td>
<td>Neuromyelitis optica [Devic]</td>
</tr>
<tr>
<td>G70.00</td>
<td>Myasthenia gravis without (acute) exacerbation</td>
</tr>
<tr>
<td>G70.01</td>
<td>Myasthenia gravis with (acute) exacerbation</td>
</tr>
</tbody>
</table>

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs), and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD):

<table>
<thead>
<tr>
<th>Jurisdiction(s): 6: K</th>
<th>NCD/LCA/LCD Document(s): A54548</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jurisdiction</td>
<td>NCD/LCA/LCD Document</td>
</tr>
</tbody>
</table>

Medicare Part B Administrative Contractor (MAC) Jurisdictions

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>E (1)</td>
<td>CA, HI, NV, AS, GU, CNMI</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>5</td>
<td>KS, NE, IA, MO</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>6</td>
<td>MN, WI, IL</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>H (4 &amp; 7)</td>
<td>LA, AR, MS, TX, OK, CO, NM</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>8</td>
<td>MI, IN</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>N (9)</td>
<td>FL, PR, VI</td>
<td>First Coast Service Options, Inc.</td>
</tr>
<tr>
<td>J (10)</td>
<td>TN, GA, AL</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>M (11)</td>
<td>NC, SC, WV, VA (excluding below)</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>L (12)</td>
<td>DE, MD, PA, NJ, DC (includes Arlington &amp; Fairfax counties and the city of Alexandria in VA)</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>K (13 &amp; 14)</td>
<td>NY, CT, MA, RI, VT, ME, NH</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>15</td>
<td>KY, OH</td>
<td>CGS Administrators, LLC</td>
</tr>
</tbody>
</table>